EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions
Can We Define High-risk DAPT Patients in USA Practice? - ppt download
The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates | tctmd.com
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy - ScienceDirect
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Synergy: Short DAPT Study - ppt download
Studying DAPT – SYNERGY Stent - Boston Scientific
Another Coronary Stent for Patients at High Bleeding Risk∗ | JACC: Cardiovascular Interventions
31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
Session evaluation and key learnings
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
Antiplatelet Therapy in High-Bleeding Risk Patients Undergoing PCI: Walking a Tightrope
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
EVOLVE Short DAPT
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect
Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives | SpringerLink
Complex Coronary Cases - ppt download
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
PDF) Evolving Concepts in Post-PCI Antiplatelets Therapy
EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
EVOLVE Short DAPT Trial Enrollment Complete - Boston Scientific
